BTBD11

Across TCGA pan-cancer cohorts, BTBD11 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BTBD11 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BTBD11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BTBD11 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where BTBD11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.351	0.938	.003	42	view →
PDAC	OS	Tertile	All	0.859	0.403	.022	3	view →
UCEC	DFS	Median	All	1.000	0.921	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BTBD11–LUAD (OS)

Open the LUAD breakdown →